Trial Profile
A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors Genentech
- 18 Jul 2012 Results published in Cancer.
- 18 Jul 2012 Primary endpoint 'Progression-free-survival-duration' has not been met according to results published in Cancer.
- 18 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.